Search

Displaying results 5311 - 5320 of 10000 in total
  1. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.

  2. Drug

    Potassium carbonate

    go.drugbank.com/drugs/DB13977
    Approved

    Potassium carbonate (K2CO3) is a white salt, soluble in water (insoluble in ethanol) which forms a strongly alkaline solution. … It can be made as the product of potassium hydroxide's absorbent reaction with carbon dioxide. It presents a large capacity to absorb moisture.

  3. Drug

    Totrombopag

    go.drugbank.com/drugs/DB05930
    Investigational

    , thus representing a significant problem in the treatment of cancer patients. … This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding

  4. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. … NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation

  5. Drug

    AD 337

    go.drugbank.com/drugs/DB05725
    Investigational

    AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia). … The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients.

  6. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  7. Drug

    CM4620

    go.drugbank.com/drugs/DB16466
    Investigational

    CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066

    Synonyms: BENZAMIDE, N-(5-(6-CHLORO-2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)-2-PYRAZINYL)-2-FLUORO-6-METHYL-, N-(5-(6-CHLORO-2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)PYRAZIN-2-YL)-2-FLUORO-6-METHYLBENZAMIDE
  8. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  9. Drug

    MP4

    go.drugbank.com/drugs/DB05313
    Investigational

    MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. … It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.

  10. Drug

    Ergosterol

    go.drugbank.com/drugs/DB04038
    ApprovedWithdrawn

    in ERGOCALCIFEROL. … A steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result